The revolution in sequencing technologies has given the momentum for the emerging genomics and personalized medicine era that led to great discoveries, particularly in cancer research. Translating these findings into the clinic, however, has moved at a much slower pace. It is evident that cancer pharmacogenomic variation, the somatic changes in cancer cells and germline variants in normal cells, influence the disease outcome and response to treatment.
The Alachkar lab focuses on applying genomic information to the identification and functional characterization of cancer targets, and in the preclinical and clinical developments of potential targeted therapeutic approaches with particular interest in acute myeloid leukemia.
